GlassScriptPhysician profile
Reem R Parseghian
NPI 1982673588
$2,547.52
in general payments reported to CMS, 2019-2025
18 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.43 · 2020: $47.62 · 2022: $146 · 2023: $222 · 2024: $162 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $480.26 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Bausch & Lomb Americas INC. | $439.77 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $346.02 | 2024-2025 | Xdemvy |
| Abbvie INC. | $312.83 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $177.36 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $149.53 | 2025 | Tearcare System |
| Coopervision INC. | $125.37 | 2022 | |
| Dompe US, INC. | $118.75 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $91.76 | 2020-2024 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $69.56 | 2023-2025 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $63.88 | 2025 | Iyuzeh |
| Rxsight INC | $42.08 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $29.74 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $25.39 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.17 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.84 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.25 | 2019 | |
| Abb Con-Cise Optical Group LLC | $15.96 | 2025 | Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Parseghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.